Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 299 results
Filters: Author is Morse, Gene D  [Clear All Filters]
Found 299 results.

Administration, Oral

Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.

Adult

Motsinger AA, Ritchie MD, Shafer RW, et al. "Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study." Pharmacogenet. Genomics. 2006;16(11):837-45.
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Verma A, Bradford Y, Verma SS, et al. "Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2017;27(3):101-111.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Demeter LM, Jiang H, A Mukherjee L, et al. "A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients." AIDS. 2009;23(3):357-68.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Ma Q, Forrest A, Rosenkranz SL, et al. "Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers." Biopharm Drug Dispos. 2008;29(2):91-101.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.

Pages